TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

In a recent study, researchers from the University of California, San Francisco, have demonstrated that high exposure to melphalan significantly increases the risk of graft-versus-host disease...

Researchers say analogous IL-17 and CSF-1 dysregulation signatures may help optimize the use of newly approved agents for the prevention and treatment of chronic graft-versus-host disease (cGVHD),...

Rovadicitinib demonstrates therapeutic potential for patients whose chronic graft-versus-host disease (cGVHD) is glucocorticoid-refractory or -dependent, researchers report.

Single-center data elucidate the benefits of using fludarabine and melphalan (FM) conditioning before peripheral blood stem cell (PBSC) transplantation and post-transplant cyclophosphamide (PTCy)...

A retrospective cohort study, conducted by researchers at the University of Freiburg, provides a comprehensive analysis of immune reconstitution and infection outcomes following allogeneic...

A recent study published in Journal for Immunotherapy of Cancer investigates the utility of DNA barcoded peptide-major histocompatibility complex (pMHC) multimers in detecting and monitoring minor...